Efficacy and Safety of Dupilumab in Atopic Dermatitis
Research highlights the need for diverse data on drug efficacy in atopic dermatitis to address barriers to treatment for patients with skin of color.
A study presented at the 34th Annual Congress of the European Academy of Dermatology and Venereology (EADV) investigated the safety and efficacy of dupilumab in pediatric patients with atopic dermatitis.
- The study analyzed data from an open-label extension analysis of dupilumab (NCT02612454) up to 3 years.
- Results showed consistent decreases in disease signs and symptoms for both White and non-White patient groups by week 152.
No direct quotes available in the text.
Autor summary: Dupilumab shows promise in treating atopic dermatitis in diverse pediatric populations.
More News
- Ionia Twp. trustees discuss potential developments - The Daily News
- The psychology behind what makes Black Friday/Cyber Monday shoppers scan and stay | News Channel 3-12
- From potholes to progress - The Daily News
- GRAPHIC: Nearly 50 birds crushed to death by truck driver, wildlife officials say
- 3 Editors Are Running The NYC Marathon. They Say They Wouldn't Have Made It Through Training Without These Products.
- Report: Ireland Stalwart Considering Shock Move To Breakway League | Balls.ie